Pharmaceutical

BlossomHill secures $100m for cancer discovery programmes 

BlossomHill has secured $100m in a Series B financing round to advance its programmes targeting cancer and autoimmune diseases.

Mar 1, 2024 - 18:00
BlossomHill secures $100m for cancer discovery programmes 
BlossomHill has secured $100m in a Series B financing round to advance its programmes targeting cancer and autoimmune diseases.
Read the original article

Tags:

Previous Article

FDA lifts two-year clinical hold on CytoDyn’s HIV trial

Next Article

1910 Genetics and Microsoft partner to enhance pharmaceutical R&D

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Walgreens isn’t acquiring anytime soon, per CEO

STAT+: Walgreens isn’t acquiring anytime soon, per CEO

Jan 8, 2024

TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan Africa for T2D

TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan...

Oct 20, 2024

STAT+: Dana-Farber deal highlights a surprising trend: New cancer centers are in vogue

STAT+: Dana-Farber deal highlights a surprising trend: ...

Sep 16, 2023